Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07850739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)

Name: Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) — clinical trial record (NCT07850739)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorNeurocrine Biosciences

Started2026-12-01

View on ClinicalTrials.gov ↗

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.

Trial Details

NCT Number	NCT07850739
Lead Sponsor	Neurocrine Biosciences
Conditions	Congenital Adrenal Hyperplasia
Enrollment	36 participants
Start Date	2026-12-01
Primary Completion	2028-03-16 (estimated)
Study Completion	2028-05-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-30